Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study
IntroductionSecond-generation integrase strand transfer inhibitors (INSTIs) are preferred treatment options worldwide, and dolutegravir (DTG) is the treatment of choice in resource-limited settings. Nevertheless, in some resource-limited settings, these drugs are not always available. An analysis of...
| Autores: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de documento: | artigo |
| Estado: | Versão publicada |
| Data de publicação: | 2023 |
| País: | España |
| Recursos: | Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau) |
| Repositório: | r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau |
| OAI Identifier: | oai:iibsantpau.fundanetsuite.com:p16377 |
| Acesso em linha: | https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=16377 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85164418847&doi=10.3389%2ffcimb.2023.1187999&partnerID=40&md5=5c8202b38b381220e5b0a64c3d9415b6 |
| Access Level: | Acceso aberto |
| Palavra-chave: | HIV integrase strand transfer inhibitors (INSTI) real-world study raltegravir elvitegravir dolutegravir |
| id |
ES_ecd5cb0d6d6ef484a5e72639ce034f35 |
|---|---|
| oai_identifier_str |
oai:iibsantpau.fundanetsuite.com:p16377 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world studySantos J.R.Casadellà M.Noguera-Julian M.Micán-Rivera R.Domingo P.Antela A.Portilla J.Sanz J.Montero-Alonso M.Navarro J.Masiá M.Valcarce-Pardeiro N.Ocampo A.Pérez-Martínez L.García-Vallecillos C.Vivancos M.J.Imaz A.Iribarren J.A.Hernández-Quero J.Villar-García J.Barrufet P.Paredes R.HIVintegrase strand transfer inhibitors (INSTI)real-world studyraltegravirelvitegravirdolutegravirIntroductionSecond-generation integrase strand transfer inhibitors (INSTIs) are preferred treatment options worldwide, and dolutegravir (DTG) is the treatment of choice in resource-limited settings. Nevertheless, in some resource-limited settings, these drugs are not always available. An analysis of the experience with the use of INSTIs in unselected adults living with HIV may be of help to make therapeutic decisions when second-generation INSTIs are not available. This study aimed to evaluate the real-life effectiveness and safety of dolutegravir (DTG), elvitegravir/cobicistat (EVG/c), and raltegravir (RAL) in a large Spanish cohort of HIV-1-infected patients. MethodsReal-world study of adults living with HIV who initiated integrase INSTIs DTG, EVG/c, and RAL-based regimens in three settings (ART-naive patients, ART-switching, and ART-salvage patients). The primary endpoint was the median time to treatment discontinuation after INSTI-based regimen initiation. Proportion of patients experiencing virological failure (VF) (defined as two consecutive viral loads (VL) & GE;200 copies/mL at 24 weeks or as a single determination of VL & GE;1,000 copies/mL while receiving DTG, EVG/c or RAL, and at least 3 months after INSTI initiation) and time to VF were also evaluated. ResultsVirological effectiveness of EVG/c- and RAL-based regimens was similar to that of DTG when given as first-line and salvage therapy. Treatment switching for reasons other than virological failure was more frequent in subjects receiving EVG/c and, in particular, RAL. Naive patients with CD4+ nadir <100 cells/& mu;L were more likely to develop VF, particularly if they initiated RAL or EVG/c. In the ART switching population, initiation of RAL and EVG/c was associated with both VF and INSTI discontinuation. There were no differences in the time to VF and INSTI discontinuation between DTG, EVG/c and RAL. Immunological parameters improved in the three groups and for the three drugs assessed. Safety and tolerability were consistent with expected safety profiles. DiscussionWhereas second-generation INSTIs are preferred treatment options worldwide, and DTG is one of the treatment of choices in resource-limited settings, first-generation INSTIs may still provide high virological and immunological effectiveness when DTG is not available.Frontiers Media S.A.2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=16377https://www.scopus.com/inward/record.uri?eid=2-s2.0-85164418847&doi=10.3389%2ffcimb.2023.1187999&partnerID=40&md5=5c8202b38b381220e5b0a64c3d9415b6Frontiers in Cellular and Infection MicrobiologyISSN: 22352988reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p163772026-06-14T12:41:47Z |
| dc.title.none.fl_str_mv |
Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study |
| title |
Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study |
| spellingShingle |
Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study Santos J.R. HIV integrase strand transfer inhibitors (INSTI) real-world study raltegravir elvitegravir dolutegravir |
| title_short |
Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study |
| title_full |
Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study |
| title_fullStr |
Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study |
| title_full_unstemmed |
Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study |
| title_sort |
Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study |
| dc.creator.none.fl_str_mv |
Santos J.R. Casadellà M. Noguera-Julian M. Micán-Rivera R. Domingo P. Antela A. Portilla J. Sanz J. Montero-Alonso M. Navarro J. Masiá M. Valcarce-Pardeiro N. Ocampo A. Pérez-Martínez L. García-Vallecillos C. Vivancos M.J. Imaz A. Iribarren J.A. Hernández-Quero J. Villar-García J. Barrufet P. Paredes R. |
| author |
Santos J.R. |
| author_facet |
Santos J.R. Casadellà M. Noguera-Julian M. Micán-Rivera R. Domingo P. Antela A. Portilla J. Sanz J. Montero-Alonso M. Navarro J. Masiá M. Valcarce-Pardeiro N. Ocampo A. Pérez-Martínez L. García-Vallecillos C. Vivancos M.J. Imaz A. Iribarren J.A. Hernández-Quero J. Villar-García J. Barrufet P. Paredes R. |
| author_role |
author |
| author2 |
Casadellà M. Noguera-Julian M. Micán-Rivera R. Domingo P. Antela A. Portilla J. Sanz J. Montero-Alonso M. Navarro J. Masiá M. Valcarce-Pardeiro N. Ocampo A. Pérez-Martínez L. García-Vallecillos C. Vivancos M.J. Imaz A. Iribarren J.A. Hernández-Quero J. Villar-García J. Barrufet P. Paredes R. |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
HIV integrase strand transfer inhibitors (INSTI) real-world study raltegravir elvitegravir dolutegravir |
| topic |
HIV integrase strand transfer inhibitors (INSTI) real-world study raltegravir elvitegravir dolutegravir |
| description |
IntroductionSecond-generation integrase strand transfer inhibitors (INSTIs) are preferred treatment options worldwide, and dolutegravir (DTG) is the treatment of choice in resource-limited settings. Nevertheless, in some resource-limited settings, these drugs are not always available. An analysis of the experience with the use of INSTIs in unselected adults living with HIV may be of help to make therapeutic decisions when second-generation INSTIs are not available. This study aimed to evaluate the real-life effectiveness and safety of dolutegravir (DTG), elvitegravir/cobicistat (EVG/c), and raltegravir (RAL) in a large Spanish cohort of HIV-1-infected patients. MethodsReal-world study of adults living with HIV who initiated integrase INSTIs DTG, EVG/c, and RAL-based regimens in three settings (ART-naive patients, ART-switching, and ART-salvage patients). The primary endpoint was the median time to treatment discontinuation after INSTI-based regimen initiation. Proportion of patients experiencing virological failure (VF) (defined as two consecutive viral loads (VL) & GE;200 copies/mL at 24 weeks or as a single determination of VL & GE;1,000 copies/mL while receiving DTG, EVG/c or RAL, and at least 3 months after INSTI initiation) and time to VF were also evaluated. ResultsVirological effectiveness of EVG/c- and RAL-based regimens was similar to that of DTG when given as first-line and salvage therapy. Treatment switching for reasons other than virological failure was more frequent in subjects receiving EVG/c and, in particular, RAL. Naive patients with CD4+ nadir <100 cells/& mu;L were more likely to develop VF, particularly if they initiated RAL or EVG/c. In the ART switching population, initiation of RAL and EVG/c was associated with both VF and INSTI discontinuation. There were no differences in the time to VF and INSTI discontinuation between DTG, EVG/c and RAL. Immunological parameters improved in the three groups and for the three drugs assessed. Safety and tolerability were consistent with expected safety profiles. DiscussionWhereas second-generation INSTIs are preferred treatment options worldwide, and DTG is one of the treatment of choices in resource-limited settings, first-generation INSTIs may still provide high virological and immunological effectiveness when DTG is not available. |
| publishDate |
2023 |
| dc.date.none.fl_str_mv |
2023 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=16377 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85164418847&doi=10.3389%2ffcimb.2023.1187999&partnerID=40&md5=5c8202b38b381220e5b0a64c3d9415b6 |
| url |
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=16377 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85164418847&doi=10.3389%2ffcimb.2023.1187999&partnerID=40&md5=5c8202b38b381220e5b0a64c3d9415b6 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Frontiers Media S.A. |
| publisher.none.fl_str_mv |
Frontiers Media S.A. |
| dc.source.none.fl_str_mv |
Frontiers in Cellular and Infection Microbiology ISSN: 22352988 reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau) |
| instname_str |
Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau) |
| reponame_str |
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau |
| collection |
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869423374061535232 |
| score |
15.812429 |